MX2021005516A - Combinacion farmaceutica que comprende un agonista selectivo del receptor s1p1. - Google Patents

Combinacion farmaceutica que comprende un agonista selectivo del receptor s1p1.

Info

Publication number
MX2021005516A
MX2021005516A MX2021005516A MX2021005516A MX2021005516A MX 2021005516 A MX2021005516 A MX 2021005516A MX 2021005516 A MX2021005516 A MX 2021005516A MX 2021005516 A MX2021005516 A MX 2021005516A MX 2021005516 A MX2021005516 A MX 2021005516A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combination
methyl
selective
receptor agonist
dioate
Prior art date
Application number
MX2021005516A
Other languages
English (en)
Inventor
Martine Clozel
Luca Piali
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2021005516A publication Critical patent/MX2021005516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención se relaciona con una combinación farmacéutica que comprende un primer ingrediente activo que es (R)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)-benz[Z]iliden]-2-([Z]-pr opilimino)-3-otolil-tiazolidin-4-ona o una sal farmacéuticamente aceptable del mismo y un segundo ingrediente activo el cual es seleccionado del grupo que consiste en metilfumarato, dimetilfumarato, (N,N-dietilcarbamoil)metil metil (2E)but-2-en-1,4-dioato y 2-(2,5-dioxopirrolidin-1-il)etil metil (2E)but-2-en-1,4-dioato o una sal farmacéuticamente aceptable del mismo.
MX2021005516A 2014-12-11 2015-12-10 Combinacion farmaceutica que comprende un agonista selectivo del receptor s1p1. MX2021005516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2014077469 2014-12-11
PCT/EP2015/079311 WO2016092042A1 (en) 2014-12-11 2015-12-10 Pharmaceutical combination comprising a selective s1p1 receptor agonist

Publications (1)

Publication Number Publication Date
MX2021005516A true MX2021005516A (es) 2022-09-27

Family

ID=54848562

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021005516A MX2021005516A (es) 2014-12-11 2015-12-10 Combinacion farmaceutica que comprende un agonista selectivo del receptor s1p1.
MX2017007651A MX2017007651A (es) 2014-12-11 2015-12-10 Combinacion farmaceutica que comprende un agonista selectivo del receptor s1p1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017007651A MX2017007651A (es) 2014-12-11 2015-12-10 Combinacion farmaceutica que comprende un agonista selectivo del receptor s1p1.

Country Status (19)

Country Link
US (5) US10245253B2 (es)
EP (1) EP3229794A1 (es)
JP (3) JP6437119B2 (es)
KR (3) KR20190077131A (es)
CN (1) CN106999462B (es)
AU (1) AU2015359306B2 (es)
BR (1) BR112017012396B1 (es)
CA (1) CA2964616C (es)
CL (1) CL2017001479A1 (es)
EA (2) EA039629B1 (es)
HK (1) HK1245106A1 (es)
IL (2) IL252701B (es)
MA (2) MA41139A (es)
MX (2) MX2021005516A (es)
PH (1) PH12017501060A1 (es)
SA (1) SA517381489B1 (es)
SG (1) SG11201704569SA (es)
UA (1) UA122063C2 (es)
WO (1) WO2016092042A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2278960T (lt) 2008-03-17 2017-02-10 Actelion Pharmaceuticals Ltd. S1p1 receptoriaus selektyvaus agonisto dozavimo režimas
KR102590068B1 (ko) 2014-12-11 2023-10-16 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
KR20230120768A (ko) 2022-02-10 2023-08-17 하나 영농조합법인 양념 핫소스와 그 제조방법

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
RU2379299C2 (ru) 2003-11-21 2010-01-20 Актелион Фармасьютиклз Лтд Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов
PL2801354T3 (pl) 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
ES2410793T3 (es) 2006-11-23 2013-07-03 Actelion Pharmaceuticals Ltd. Nuevo procedimiento para la preparación de derivados de 2-imino-tiazolidin-4-ona
EP2137537B8 (en) 2007-02-08 2016-06-01 Biogen MA Inc. Compositions and Uses for Treating Multiple Sclerosis
LT2278960T (lt) 2008-03-17 2017-02-10 Actelion Pharmaceuticals Ltd. S1p1 receptoriaus selektyvaus agonisto dozavimo režimas
NZ602496A (en) * 2008-08-19 2013-09-27 Xenoport Inc Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
SI2379063T2 (sl) 2009-01-09 2021-09-30 Fwp Ip Aps Farmacevtska formulacija, ki obsega enega ali več estrov fumarne kisline v tableti v erozivnem matriksu
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
US20100260755A1 (en) 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
BR112012013092A2 (pt) 2009-12-01 2016-10-25 Metanomics Health Gmbh ''métodos de diagnóstico, método para identificar se um indivíduo necessita de uma terapia contra esclerose múltipla, métodos de determinação e previsão relacionados à esclerose múltipla''
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
WO2012162669A1 (en) * 2011-05-26 2012-11-29 Biogen Idec Ma Inc. Methods of treating multiple sclerosis and preserving and/or increasing myelin content
JP2014517300A (ja) 2011-05-31 2014-07-17 メタノミクス ヘルス ゲーエムベーハー 多発性硬化症を診断する方法
BR112014019462B1 (pt) 2012-02-07 2022-03-22 Biogen Ma Inc. Composições farmacêuticas contendo fumarato de dimetila
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
US20130314669A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Method and system for assessing visual disorder
US9550798B2 (en) 2012-07-27 2017-01-24 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
ES2660287T3 (es) 2012-08-06 2018-03-21 Biogen Ma Inc. Compuestos que son agentes moduladores de s1p y/o agentes moduladores de atx
EP2879673B1 (en) 2012-08-06 2018-07-25 Biogen MA Inc. 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders
EP2883177A1 (en) 2012-08-13 2015-06-17 Biogen Idec MA Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
EP2885266B1 (en) 2012-08-17 2020-03-18 Actelion Pharmaceuticals Ltd Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
EP2887933A1 (en) * 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CN104870014A (zh) 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
US20150157590A9 (en) * 2012-11-05 2015-06-11 Xenoport, Inc. Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
US8669281B1 (en) * 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
EP2970101B1 (en) 2013-03-14 2018-06-06 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various deseases
US20170165236A1 (en) 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
KR102590068B1 (ko) 2014-12-11 2023-10-16 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생

Also Published As

Publication number Publication date
US20210338640A1 (en) 2021-11-04
KR20190077131A (ko) 2019-07-02
SA517381489B1 (ar) 2022-03-13
AU2015359306A1 (en) 2017-07-27
US20190175563A1 (en) 2019-06-13
EA201791260A1 (ru) 2017-10-31
US11026927B2 (en) 2021-06-08
JP7033642B2 (ja) 2022-03-10
US11672783B2 (en) 2023-06-13
MA41481A (fr) 2017-12-19
JP6437119B2 (ja) 2018-12-12
JP6846392B2 (ja) 2021-03-24
EA202290017A1 (ru) 2022-03-22
EP3229794A1 (en) 2017-10-18
KR20210122315A (ko) 2021-10-08
BR112017012396A2 (pt) 2018-04-24
CA2964616A1 (en) 2016-06-16
JP2019011343A (ja) 2019-01-24
KR101996245B1 (ko) 2019-07-05
PH12017501060B1 (en) 2018-03-05
CN106999462B (zh) 2020-10-23
JP2017537129A (ja) 2017-12-14
PH12017501060A1 (en) 2018-03-05
US20170348287A1 (en) 2017-12-07
AU2015359306B2 (en) 2020-07-23
IL288907A (en) 2022-02-01
HK1245106A1 (zh) 2018-08-24
IL252701B (en) 2022-01-01
CL2017001479A1 (es) 2018-02-09
CA2964616C (en) 2020-01-28
JP2021059574A (ja) 2021-04-15
US10245253B2 (en) 2019-04-02
EA039629B1 (ru) 2022-02-18
CN106999462A (zh) 2017-08-01
MA41481B1 (fr) 2022-03-31
BR112017012396B1 (pt) 2023-12-12
US20240131009A1 (en) 2024-04-25
WO2016092042A1 (en) 2016-06-16
MA41139A (fr) 2017-10-17
SG11201704569SA (en) 2017-07-28
US20240139160A1 (en) 2024-05-02
IL252701A0 (en) 2017-08-31
UA122063C2 (uk) 2020-09-10
MX2017007651A (es) 2017-10-11
KR20170095302A (ko) 2017-08-22

Similar Documents

Publication Publication Date Title
PH12017501060A1 (en) Pharmaceutical combination comprising a selective s1p1 receptor agonist
NO2022023I1 (no) Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dih ydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolylthiazolidin-4-one) and harmaceutically acceptable salts thereof
EP4201399A3 (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
EP3706774A4 (en) GLP-2 ANALOGUES AND PEPTIBODIES FOR USE BEFORE, DURING OR AFTER SURGICAL PROCEDURE
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
MY190849A (en) Methods of treating multiple sclerosis
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
EP3845516A4 (en) NEW HIF-1alfa INHIBITOR, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING THE SAME AS AN ACTIVE INGREDIENT
IL240136B (en) Pharmaceutical preparations containing n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a salt Pharmacists accept, solvate or its dissolved salt
PH12016502527B1 (en) Stabilized desmopressin
EP3530269A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES AND / OR HYPERLIPIDEMIA COMPRISING MIDORINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT
TH172011B (th) เภสัชภัณฑ์รวมที่ประกอบรวมด้วยอะกอนิสต์ซึ่งเลือกออกฤทธิ์ต่อ s1p1 รีเซปเตอร์
TH172011A (th) เภสัชภัณฑ์รวมที่ประกอบรวมด้วยอะกอนิสต์ซึ่งเลือกออกฤทธิ์ต่อ s1p1 รีเซปเตอร์
EP3686185A4 (en) FLORINE-DERIVATIVE OR PHARMACEUTICAL SALT THEREOF, MANUFACTURING METHOD FOR ITS AND PHARMACEUTICAL COMPOSITION THEREOF, AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF HCV-ASSOCIATED DISEASES
ZA202206112B (en) Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition comprising same as active agent
EP3818980A4 (en) PHARMACEUTICAL COMPOSITION WITH INDIRUBIN DERIVATE AS THE ACTIVE SUBSTANCE
EP3795170A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE
EP3363799A4 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof